Nuvalent, Inc. · 4 hours ago
Senior Director, Tax and Treasury
United States
Full-time
Remote
Director/Executive
$275K/yr - $300K/yr
12+ years expNuvalent, Inc. is an early-stage company focused on creating selective medicines for cancer patients. They are seeking a Senior Director of Tax and Treasury to lead tax and treasury matters, develop strategic tax planning, and manage the company's treasury portfolio for optimal liquidity and risk management.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Develop and execute appropriate tax planning strategies and recommendations in partnership with external tax advisors that align with the company’s long-term business objectives
Advise senior leadership on the tax implications of key business decisions, including providing analysis of the tax impact of proposed transactions and developing tax efficient solutions
Proactively monitor and analyze changes in tax law to identify potential planning opportunities or issues, and communicate their impact on the company
Lead special tax projects or studies such as transfer pricing, R&D tax credits, and/or other ad hoc initiatives, as needed
Collaborate with our third-party tax provider to accurately and timely prepare the filings of all federal, state, and local income tax returns, estimated payments, and extensions
Manage any tax disputes, resolve notices and drive continuous improvement to reduce recurring issues, as needed
Ensure all cross-border transactions are properly documented and supported for tax filing purposes
Provide timely and accurate responses to tax-related inquiries from cross-functional teams
Manage third-party tax provider on the quarterly and annual income tax provision process in accordance with ASC 740
Collaborate with Financial Reporting to ensure all tax-related disclosures in SEC filings (10-Q, 10-K) are prepared accurately and in compliance with US GAAP
Maintain robust internal controls and documentation over tax processes, ensuring compliance with SOX 404(b) requirements and clear roles and responsibilities with relevant stakeholders
Collaborate with external auditors and advisors to ensure a smooth and efficient tax reporting and compliance process, proactively implementing process improvements as needed
Oversee global cash management and all banking, insurance and investment management partner relationships
Evaluate treasury policies and procedures, identifying continuous improvement opportunities and leading implementation of treasury best practices
Collaborate with FP&A on global cash management activities to ensure cash flows support current and future operational needs
Manage fixed income investment portfolio and foreign exchange risk in line with corporate policies
Oversee treasury management systems and controls to ensure compliance and efficiency
Perform financial analysis of investment positions with an emphasis on maximizing return and improving liquidity, while minimizing risk
Advise management on short-term and long-term financial objectives, policies, and actions
Qualification
Required
Bachelor's degree in Finance, Accounting, or related field
12+ years of progressive tax experience, with a mix of Big 4 and in-house corporate experience, ideally in the life sciences or biotech industry
Strong technical knowledge of US federal and state tax law, ASC 740, and international tax regulations
Experience with indirect taxes
Experience working at a public company, SOX 404(b)-compliant environment
Preferred
CPA or MST preferred
Global treasury experience strongly preferred
Benefits
Medical, dental, and vision insurance
401(k) retirement savings plan
Generous paid time off (including a summer and winter company shutdown)
Company
Nuvalent, Inc.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$1.82BKey Investors
Bain Capital Life SciencesDeerfield
2025-11-18Post Ipo Secondary· $500M
2024-09-16Post Ipo Equity· $575M
2023-10-16Post Ipo Equity· $300M
Leadership Team
James Porter
CEO
Alexandra Balcom
Chief Financial Officer
Recent News
MarketScreener
2025-12-16
Company data provided by crunchbase